Company Announcement - Pelthos Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on March 19, 2026 [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day, followed by a question-and-answer session [1] Conference Call Details - The conference call will be accessible via toll-free number 1-877-451-6152 and international number 1-201-389-0879, with a conference ID of 13758894 [2] - A webcast of the conference call will be available at the provided link [2] Company Overview - Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on developing products for cutaneous infectious diseases [2] - The lead product, ZELSUVMI™ (berdazimer) topical gel, is the first prescription therapy approved for home use to treat Molluscum contagiosum [2] - The product portfolio also includes Xepi® (ozenoxacin) Cream for impetigo and Xeglyze® (abametapir) for head lice [2]
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Globenewswire·2026-03-09 12:30